{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:51:27Z","timestamp":1763686287683,"version":"3.44.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.urology.2021.08.008","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T01:18:31Z","timestamp":1629595111000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Does Switching Bacillus Calmette-Guerin Strains During Maintenance Therapy Affect the Outcome in Non-Muscle Invasive Bladder Cancer?"],"prefix":"10.1016","volume":"158","author":[{"given":"Evren","family":"S\u00fcer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat Can","family":"Karaburun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muammer","family":"Babayi\u011fit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7a\u011fr\u0131","family":"Akp\u0131nar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet \u0130lker","family":"G\u00f6k\u00e7e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6mer","family":"G\u00fclp\u0131nar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadir","family":"T\u00fcrk\u00f6lmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00fcmer","family":"Baltac\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2021.08.008_bib0001","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.08.008_bib0002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, Version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.urology.2021.08.008_bib0003","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.170.3963.1217","article-title":"Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG)","volume":"170","author":"Zbar","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.urology.2021.08.008_bib0004","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette\u2013Guerin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2021.08.008_bib0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1473-3099(02)00182-2","article-title":"BCG\u2014different strains, different vaccines?","volume":"2","author":"Behr","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.urology.2021.08.008_bib0006","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2021.08.008_bib0007","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2021.08.008_bib0008","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.08.008_bib0009","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and update for S1602 \u201cA phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-na\u00efve high-grade non-muscle-invasive bladder cancer","volume":"4","author":"Svatek","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2021.08.008_bib0010","doi-asserted-by":"crossref","unstructured":"Mostafid AH, Redorta JP, Sylvester R, et\u00a0al. Therapeutic options in high-risk non\u2013muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Gu\u00e9rin. 2015","DOI":"10.1016\/j.eururo.2014.11.031"},{"key":"10.1016\/j.urology.2021.08.008_bib0011","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non\u2013muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.08.008_bib0012","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study","volume":"163","author":"LAMM","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2021.08.008_bib0013","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2021.08.008_bib0014","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urology.2021.08.008_bib0015","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","author":"Stuart","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.urology.2021.08.008_bib0016","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of bacillus calmette-guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.08.008_bib0017","first-page":"8788","article-title":"BCG: a throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy","volume":"24","author":"Morales","year":"2017","journal-title":"Can J Urol"},{"key":"10.1016\/j.urology.2021.08.008_bib0018","first-page":"484","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non\u2013muscle-invasive bladder cancer","author":"Witjes","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2021.08.008_bib0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ucl.2013.01.012","article-title":"Strategies for optimizing bacillus Calmette-Guerin","volume":"40","author":"Shah","year":"2013","journal-title":"Urol Clin"},{"key":"10.1016\/j.urology.2021.08.008_bib0020","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429521007810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429521007810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:32:10Z","timestamp":1758767530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429521007810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":20,"alternative-id":["S0090429521007810"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2021.08.008","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Switching Bacillus Calmette-Guerin Strains During Maintenance Therapy Affect the Outcome in Non-Muscle Invasive Bladder Cancer?","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2021.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}